Regeneron cyclodextrin protein drug conjugates
Summary
USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.
What changed
USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals, Inc. for cyclodextrin-based linker-payloads and protein conjugates for treating diseases including proliferative conditions. The patent includes 41 claims covering compounds, compositions, and methods that reduce side-effects from non-specific binding to non-target cells. Application No. 17837598 was filed June 10, 2022.
Pharmaceutical companies and drug manufacturers developing cyclodextrin-based drug delivery systems or protein conjugates should review this patent to assess potential freedom-to-operate concerns. Competitors in the same therapeutic space (A61P 35/00 - anti-cancer, A61P 29/00 - anti-inflammatory) may need to consider licensing or design-around strategies. This is an informational patent grant announcement with no immediate compliance obligations.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Cyclodextrin protein drug conjugates
Grant US12589101B2 Kind: B2 Mar 31, 2026
Assignee
Regeneron Pharmaceuticals, Inc.
Inventors
Amy Han, William Olson
Abstract
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.
CPC Classifications
A61K 31/573 A61K 47/61 A61K 47/6889 A61K 47/6807 A61K 47/6851 A61K 47/6803 A61K 47/6817 A61K 47/6849 A61K 47/68031 A61K 31/724 A61P 3/00 A61P 25/00 A61P 29/00 A61P 35/00 A61P 35/04 C07J 43/003 C07J 71/0031
Filing Date
2022-06-10
Application No.
17837598
Claims
41
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.